Peer-assisted telemedicine hepatitis-C treatment for people who use drugs in rural communities: a mixed methods study by Kim Hoffman, Gillian Leichtling, Sarah Shin, Andrew Seaman, Tonhi Gailey, Hunter C. Spencer, P. Todd Korthuis

“…Abstract Background The increase in opioid use disorder among young, nonurban people has fueled sharp rises in hepatitis C virus (HCV) infections. Innovative treatment models are needed that circumvent healthcare system barriers for people who use drugs (PWUD), particularly in rural areas. …”
Get full text

Genotype 3 is linked to worse liver disease progression in hepatitis C patients even after SVR following DAA therapy by Xiping Ran, Xiping Ran, Yang Xu, Ying Wang, Cheng Zeng, Chen Gong, Ni Wang, Dachuan Cai, Dachuan Cai

Subjects: “…hepatitis C virus…”
Get full text

Efficacy and Safety of a Novel Pegylated Interferon Alpha-2a in Egyptian Patients with Genotype 4 Chronic Hepatitis C by Alaa Awad Taha, Ahmad El-Ray, Maged El-Ghannam, Bahaa Mounir

“…BACKGROUND: Hepatitis C virus (HCV) genotype 4 is a common infection in Egypt and is the leading cause of liver disease.…”
Get full text

Prevalence of hepatitis C virus antibodies and associated risks among residents in long-term assisted living facilities and shelters in Latvia by Ieva Tolmane, Ieva Siksaliete, Inga Upmace, Inga Bulmistre, Agita Jeruma, Inga Azina, Baiba Rozentale, Raimonds Sīmanis

Subjects: “…hepatitis c virus…”
Get full text

Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study by Hanan M. Fayed, Ali A. Ghweil, Mona M. AbdelMeguid

“…We aimed to investigate changes in the circulating monocyte phenotypes in response to Daclatasvir-Sofosbuvir (SOF/DCV) therapy in chronic hepatitis C (CHC) and relate findings to the viral kinetics and the fibrosis score. …”
Get full text

Mortality among Alaska Native Adults with Confirmed Hepatitis C Virus Infection Compared with the General Population in Alaska, 1995–2016 by Sara S. Bressler, Dana Bruden, Leisha D. Nolen, Michael G. Bruce, Lisa Towshend-Bulson, Philip Spradling, Brian J. McMahon

“…Background. Hepatitis C virus (HCV) infection incidence rates in the United States have increased since 2010 as a byproduct of the opioid crisis despite the introduction of direct-acting antiviral agents in 2013. …”
Get full text

Development of Virus-Like Particles (VLPs) for Hepatitis C Virus genotype 4: a novel approach for vaccine development in Egypt by Ahmed A. Ali, Rasha A. M. Azouz, Nahla A. Hussein, Reem El-Shenawy, Naiera M. Helmy, Yasmine S. El-Abd, Ashraf A. Tabll

Subjects: “…Hepatitis C Virus (HCV)…”
Get full text

Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease by Anna Maruyama, Trana Hussaini, Nilufar Partovi, Siegfried R. Erb, Vladimir Marquez Azalgara, Nadia Zalunardo, Neora Pick, Mark Hull, Eric M. Yoshida

“…Although major advances have occurred in treating patients with hepatitis C virus (HCV) with the development of new direct-acting antivirals (DAAs), treatment of liver transplant recipients with HCV, human immunodeficiency virus (HIV) coinfection, and renal disease is challenging due to the lack of efficacy and safety data in this population. …”
Get full text

Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada by Sergio M Borgia, Adenike Rowaiye

“…BACKGROUND: All oral, highly effective direct-acting antiviral combinations, such as sofosbuvir-ledipasvir, have recently been licensed in Canada but cost as much as $67,000 for a 12-week course of therapy, representing a major economic barrier to predominately single-payer health care systems such as that found in Ontario. In hepatitis C virus (HCV) genotype 1 noncirrhotic patients with a baseline viral load of <6×106 IU/mL, treatment with sofosbuvir-ledipasvir can be shortened to eight weeks without compromising ≥95% efficacy. …”
Get full text

Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study by D. T. Abrurakhmanov, V. G. Morozov, I. G. Nikitin, P. O. Bogomolov, N. I. Geyvandova, Ye. N. Bessonova, I. G. Bakulin, V. A. Isakov, K. V. Zhdanov, M. V. Mayevskaya, Ye. A. Nurmukhametova, E. Z. Burnevich, Ye. V. Chesnokov, V. D. Pasechnikov, A. Hill, I. Lonjon-Domanec, S. N. Kizhlo

“…In 153 patients with severe liver fibrosis caused by hepatitis C virus (genotype 1), on background of triple AVT with telaprevir high level of immediate virologic response and low level of the preterm treatment discontinuation was marked.…”
Get full text

Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients by Carla De Benedittis, Mattia Bellan, Martina Crevola, Elena Boin, Matteo Nazzareno Barbaglia, Venkata Ramana Mallela, Paolo Ravanini, Elisa Ceriani, Stefano Fangazio, Pier Paolo Sainaghi, Michela Emma Burlone, Rosalba Minisini, Mario Pirisi

“…The interplay between the two genes may explain some of the controversy on this topic and may be exploited to stratify HCC risk in hepatitis C.…”
Get full text

Validity of serum autotaxin and Doppler ultrasound as noninvasive markers of esophageal varices in patients with liver cirrhosis by Doaa El Wazzan, Ayman F. El-Shayeb, Soraya Hamouda, Mohamed El Shafei, Akram A. Degheidy, Basma Salem, Mohamed Adel

Subjects: “…Hepatitis C virus…”
Get full text

Comparison of the performances between ChatGPT and Gemini in answering questions on viral hepatitis by Meryem Sahin Ozdemir, Yusuf Emre Ozdemir

Subjects: Get full text

Results of the ORION open comparative randomized trial: evaluation of efficacy of the Russian drugs Altevir and Phosphogliv in combined treatment of chronic hepatitis C by V. T. Ivashkin, M. V. Mayevskaya, P. O. Bogomolov, I. G. Nikitin, A. O. Buyeverov, A. V. Lapshin

Subjects: “…chronic hepatitis c…”
Get full text

Efficacy and safety of the first domestic pegilated interferon alpha-2b «Pegaltevir» at chronic hepatitis C: pilot data of phase III clinical study by V. T. Ivashkin, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, M. V. Mayevskaya, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda

Subjects: “…chronic hepatitis c…”
Get full text

Preliminary results of open comparative randomized study PHG-M3/P01-09 «ORION» on application of «Phosphogliv» in combined therapy of chronic hepatitis C by M. V. Mayevskaya

Subjects: “…chronic hepatitis c…”
Get full text

Prevalence of Hepatitis C Virus Infection in Cancer Patients: A Cross-sectional Study from Regional Cancer Care Centre, Gujarat, India by Hirenkumar Ashokbhai Patel, Foram Maulin Patel

Subjects: Get full text

SUPPRESSION OF SUBGENOMIC HEPATITIS C VIRUS RNA REPLICON REPLICATION IN Huh-7 CELLS BY THE NS3 PROTEASE INHIBITOR SCH5030334: A STOCHASTIC MATHEMATICAL MODEL by E. L. Mishchenko, N. V. Ivanisenko, I. R. Akberdin, P. S. Demenkov, V. A. Likhoshvai, N. A. Kolchanov, V. A. Ivanisenko

Subjects: “…hepatitis c virus…”
Get full text

Seroprevalence of TORCH Viral Agents in Pregnant Women in Turkey: Systematic Review and Meta-Analysis by Elmas Pinar Kahraman Kilbas, Ihsan Hakki Ciftci, Imdat Kilbas, Hande Toptan

Subjects: Get full text

Restoration of Innate and Adaptive Immune Responses by HCV Viral Inhibition with an Induction Approach Using Natural Interferon-Beta in Chronic Hepatitis C by Y. Kishida, N. Imaizumi, H. Tanimura, Y. Haruna, S. Kashiwamura, T. Kashiwagi

“…Chronic hepatitis C (CHC) is a serious medical problem necessitating more effective treatment. …”
Get full text